



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/982,284	12/01/1997	HENRYK LUBON	030523/0141	9099

7590 01/31/2003

FOLEY & LARDNER
3000 K Street Suite 500
Washington, DC 20007-5109

EXAMINER

WILSON, MICHAEL C

ART UNIT	PAPER NUMBER
1632	36

DATE MAILED: 01/31/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.
08/982,284

Applicant(s)

Lubon et al.

Examiner
Michael C. Wilson

Art Unit
1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 7-8-02 and 11-18-02

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

4) Claim(s) 75-100 is/are pending in the application.

4a) Of the above, claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 75-100 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claims _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some* c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. _____.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) Notice of References Cited (PTO-892)

4) Interview Summary (PTO-413) Paper No(s). _____

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

5) Notice of Informal Patent Application (PTO-152)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____

6) Other: _____

Art Unit: 1632

DETAILED ACTION

The Art Unit location of your application in the USPTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Art Unit 1632.

Continued Prosecution Application

The request filed on 7-8-02, paper number 32, for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 08/982,284 is acceptable in view of the filing fee sent 11-18-02, paper number 35, and a CPA has been established.

No amendments have been filed, and no arguments have been provided. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 75-100 remain pending and under consideration in the instant application.

Claim Objections

“...an uromodulin” should be “a uromodulin” (claims 75, 80, 83, 88, 93, 96).

“...an urinary kallikrein” should be “a urinary kallikrein” (claims 75, 80, 83, 88, 93, 96).

“...an urinary thrombomodulin” should be “a urinary thrombomodulin” (claims 75, 80, 83, 88, 93, 96).

“...an uropontin” should be “a uropontin” (claims 75, 80, 83, 88, 93, 96).

There should be a comma after “nephrocalcin gene” in claims 75, 80, 83, 88, 93, 96.

Art Unit: 1632

There should be a comma after “bone morphogenetic protein” in claims 86 and 99.

Claim Rejections - 35 USC § 112

1. Claims 75-100 remain rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention for reasons of record.
2. Claims 75-100 remain rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a transgenic non-human mammal whose genome comprises a transgene comprising a nucleic acid sequence encoding a protein operatively linked to a promoter that causes secretion of the protein into the urine of the transgenic mammal, wherein said protein is expressed and secreted into the urine of said transgenic non-human mammal and a method of producing a protein in the urine of said non-human mammal, does not reasonably provide enablement for using 5' regulatory sequences of the uromodulin, renin, erythropoietin, apolipoprotein E, osteopontin, urinary kallikrein, urinary thrombomodulin, uropontin, nephrocalcin or aquaporin genes to obtain expression or secretion of exogenous protein in the urine of transgenic non-human mammals, using any 3' regulatory sequences to obtain exogenous protein expression in the urine, or expressing an enzyme in the urine of transgenic non-human mammals. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention

Art Unit: 1632

commensurate in scope with these claims for reasons of record. It is readily apparent that the heading in the previous enablement rejection listing claims 5-7, 11-13, 15, 45-47, 51-57, 61-65 and 67-74 was in error and should have been the pending claims 75-100.

3. Claims 75-100 remain rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. It is readily apparent that the heading in the previous indefiniteness rejection listing claims 6, 11, 45, 56, 69, 70, 73 and 74 was in error and should have been the pending claims 75-100 as discussed throughout the rejection.

Conclusion

This is a CPA of applicant's earlier Application No. 08/982284. All claims are drawn to the same invention claimed in the earlier application and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the earlier application. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action in this case. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period

Art Unit: 1632

will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no, however, event will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

No claim is allowed.

Inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Wilson who can normally be reached on Monday through Friday from 9:00 am to 5:30 pm at (703) 305-0120.

Questions of formal matters can be directed to the patent analyst, Dianiece Jacobs, who can normally be reached on Monday through Friday from 9:00 am to 5:30 pm at (703) 305-3388.

Questions of a general nature relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1235.

If attempts to reach the examiner, patent analyst or Group receptionist are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached on (703) 305-4051.

The official fax number for this Group is (703) 308-4242.

Michael C. Wilson



MICHAEL C. WILSON
PATENT EXAMINER